Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, randomized, double-blind, placebo controlled Phase 1 study to assess the safety, tolerability, PK and PD of single and multiple ascending oral doses of HP501 in Chinese healthy participants and a drug-drug interaction study to assess the effect of HP501 on the pharmac

Next Previous
Trial Profile

A single-center, randomized, double-blind, placebo controlled Phase 1 study to assess the safety, tolerability, PK and PD of single and multiple ascending oral doses of HP501 in Chinese healthy participants and a drug-drug interaction study to assess the effect of HP501 on the pharmac

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HP 501 (Primary) ; Febuxostat
  • Indications Gout; Hyperuricaemia
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 02 Feb 2022 Results published in the Journal of Clinical Endocrinology and Metabolism
  • 19 Jun 2020 According to a Hinova pharmaceuticals media release, the first dose was given to the healthy volunteers in the Huaxi (West China) hospital on June 19, 2019.
  • 25 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top